Wolgen has already said they will try to use the data from PASS and other sources to bolster an application for Prenumbra.
That is totally routine for all drug approvals.
Five years seems outlandish, they are slated to finish the program in 2023, two years from now.
It is the normal FDA approval time. In fact it often takes much longer.
HC is a place where men (very rarely women) with limited education and no relevant professional experience imagine they are experts on extremely complex technical and regulatory issues. In the vast majority of cases holders rosy predictions turn out to be totally wrong.
Revenue EXPLOSION Coming?, page-49
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |